EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Ruth Salim, Christian Winther Eskelund iD, Mats Jerkeman, Arne Kolstad, Riikka Räty, Christian Geisler, Martin Hutchings, Carsten Utoft Niemann, Lone Bredo Pedersen, Jonas Raaschou-Pedersen, Eileen Wedge, Juan Luis García-Rodríguez iD und 3 weitere

Genes · 2025

DOI: 10.3390/genes16060634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Ruth Salim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Biomarkers, Tumor, RNA, Circular, Neoplasm Recurrence, Local. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anita and Tage Therkelsens fund, Amalie Jørgensens Memorial Grant, Anita and Tage Therkelsens Fund and Amalie Jørgensens Memorial Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Mantle cell lymphoma (MCL) is a highly heterogenous disease, but an optimal prognostic biomarker in relapsed/refractory (R/R) MCL has not yet been established. The circular RNA-based risk score, circSCORE, was recently proposed as a promising prognosticator in newly diagnosed, younger patients with MCL. This study explores the prognostic potential of circSCORE in R/R MCL in both nodal (lymph node (LN)) and non-nodal tissues (bone marrow (BM)) and peripheral blood (PB)). Materials and Methods: RNA was extracted from 65 relapse samples consisting of first-relapse LN samples (n = 20) from patients who previously underwent first-line treatment in the MCL2 and MCL3 trials, and either BM (n = 34) or PB (n = 11) samples obtained from patients with R/R MCL included in the MCL6 trial, taken at trial baseline. Kaplan–Meier estimates, and Cox regressions were used to evaluate the association between circSCORE risk groups (high versus low) and outcomes.

Results

Survival analyses showed significantly inferior outcomes for patients with high-risk circSCORE compared to low-risk score for both progression-free survival (PFS) (hazard ratio (HR) 1.99, p-value 0.0407) and overall survival (OS) (HR 2.29, p-value 0.0192) in the total cohort. The same tendencies were displayed when exploring the non-nodal samples only. Furthermore, circSCORE retained prognostic impact for PFS, but not OS, when adjusted for Ki67, MIPI, and TP53 mutation status.

Conclusions

The circRNA-based risk score, circSCORE, displayed prognostic potential in R/R MCL along with promising application in non-nodal tissues, indicating that circSCORE, if further validated, might serve as an easily obtainable biomarker in R/R MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellBiomarkers, TumorRNA, CircularNeoplasm Recurrence, LocalHumansFemaleMalePrognosisMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

NanoStringbiomarkercircRNAcircSCOREmantle cell lymphomancRNArelapse/refractory diseaserisk score

Substanzen

Biomarkers, TumorRNA, Circular

Autor:innen und Institutionen

  • Department of Hematology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Biotech Research and Innovation Centre, BRIC, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Department of Oncology, Skane University Hospital, SE-221 00 Lund, Sweden.
  • Department of Oncology, Division Gjøvik-Lillehammer, Innlandet Hospital Trust, 2819 Gjøvik, Norway.
  • Department of Hematology, Helsinki University Hospital, 00029 Helsinki, Finland.
  • Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

ORCID-Profile: Christian Winther Eskelund, Juan Luis García-Rodríguez, Kirsten Grønbæk

Förderung

  • Anita and Tage Therkelsens fund
  • Amalie Jørgensens Memorial Grant
  • Anita and Tage Therkelsens Fund and Amalie Jørgensens Memorial Grant
  • Danish Cancer Society (Danish Research Center for Precision Medicine in Blood Cancer
  • Lundbeck Foundation

Zitieren

APA

Salim, R., Eskelund, C. W., Jerkeman, M., Kolstad, A., Räty, R., Geisler, C., Hutchings, M., Niemann, C. U., Pedersen, L. B., Raaschou-Pedersen, J., Wedge, E., García-Rodríguez, J. L., Kristensen, L. S., Dahl, M., & Grønbæk, K. (2025). Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Genes. https://doi.org/10.3390/genes16060634

Vancouver

Salim R, Eskelund CW, Jerkeman M, Kolstad A, Räty R, Geisler C, et al. Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Genes. 2025. doi:10.3390/genes16060634

BibTeX
@article{Salim2025,
  author = {Salim, Ruth and Eskelund, Christian Winther and Jerkeman, Mats and Kolstad, Arne and Räty, Riikka and Geisler, Christian and Hutchings, Martin and Niemann, Carsten Utoft and Pedersen, Lone Bredo and Raaschou-Pedersen, Jonas and Wedge, Eileen and García-Rodríguez, Juan Luis and Kristensen, Lasse Sommer and Dahl, Mette and Grønbæk, Kirsten},
  title = {Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16060634}
}
Kostenlos starten →